Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24820758 | 1.00 | CYP3A4 (0.64) | CYP3A4CYP2C9PKMCYP2C19FKBP1A | |
| SCHEMBL7302729 | 1.00 | CYP3A4 (0.64) | CYP3A4CYP2C9PKMCYP2C19FKBP1A | |
| SCHEMBL21696782 | 0.96 | FKBP1A (0.61) | CYP3A4CYP2C9PKMCYP2C19FKBP1A | |
| SCHEMBL21697064 | 0.89 | ALDH1A1 (0.54) | CYP3A4CYP2C9PKMCYP2C19FKBP1A | |
| SCHEMBL20111166 | 0.88 | HDAC1 (0.61) | CYP3A4CYP2C9PKMCYP2C19ALDH1A1 | |
| SCHEMBL21696527 | 0.87 | CYP3A4 (0.66) | CYP3A4CYP2C9PKMCYP2C19ALDH1A1 | |
| SCHEMBL21697246 | 0.87 | FKBP1A (0.58) | CYP3A4CYP2C9PKMCYP2C19FKBP1A | |
| SCHEMBL21696758 | 0.87 | FKBP1A (0.58) | CYP3A4CYP2C9PKMCYP2C19FKBP1A | |
| SCHEMBL21696570 | 0.86 | MEN1 (0.57) | CYP3A4CYP2C9PKMCYP2C19ALDH1A1 | |
| SCHEMBL21430529 | 0.86 | CYP3A4 (0.52) | CYP3A4CYP2C9PKMCYP2C19FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038501-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8865756-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140127762-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALPHA-SUBSTITUTED PROLINE | API CORPORATION (JP) | 2014-05-08 | — | — | US | disclosed |
| US-20130296311-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296311-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | CYP3A4 2538/4885CYP2C9 3984/4885PKM 4441/4885 |
| US-20150038501-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | CYP3A4 2538/4885CYP2C9 3984/4885PKM 4441/4885 |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | CYP3A4 2538/4885CYP2C9 3984/4885PKM 4441/4885 |
| US-20140127762-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALPHA-SUBSTITUTED PROLINE | PREP, NPEPPS, DNPEP | CYP3A4 2195/4885CYP2C9 1843/4885PKM 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.